targeted-therapy

Tunlametinib / HL-085

A China NMPA conditionally approved MEK inhibitor for advanced NRAS-mutant melanoma after anti-PD-1/PD-L1 treatment failure. Availability outside China should not be assumed.

Plain-English summary

Tunlametinib is a selective MEK1/2 inhibitor studied in advanced NRAS-mutant melanoma. MatchMedi treats it as China-specific and source-dependent, not a global standard option.

What the sources say

• China NMPA says tunlametinib capsules, Chinese trade name 科露平, received conditional marketing approval with priority review for advanced melanoma with NRAS mutation after anti-PD-1/PD-L1 treatment failure.
• ClinicalTrials.gov lists NCT03973151 as a completed phase I/II study of HL-085 in NRAS-mutant advanced melanoma.
• ClinicalTrials.gov lists NCT06008106 as a recruiting phase III trial comparing tunlametinib with investigator-chosen combination chemotherapy in advanced NRAS-mutant melanoma after prior immunotherapy.
• The exact tunlametinib plus nivolumab melanoma combination remains a lived-context and research lead until a trial record or publication is identified.

When this commonly comes up

• NRAS-mutant advanced melanoma is being treated in or through China.
• Prior PD-1 / PD-L1 treatment has failed.
• A physician is discussing a MEK inhibitor, alone or with a PD-1 inhibitor.
• A family is comparing a China-specific regulatory option with clinical trials in another country.

What this does not mean

• It does not mean the medicine is available globally.
• It does not prove that combining it with nivolumab is standard care.
• A short response in one patient does not predict another patient's response.

Important cautions

• Do not assume availability outside China.
• If combined with nivolumab or pembrolizumab, ask whether this MEK inhibitor + PD-1 inhibitor combination is trial-based, protocol-based, compassionate use, or off-label.
• Responses may be temporary; ask the oncology team how progression, duration of response, or acquired resistance will be monitored.
• NCT06008106 excludes prior MEK-inhibitor treatment, so prior exposure can matter when asking whether a later trial fits.

Questions to ask

• Is this exactly tunlametinib / HL-085 / 妥拉美替尼?
• Is it being prescribed after PD-1/PD-L1 treatment failure?
• Is it being used alone or with nivolumab?
• Is the combination being described as MEK inhibitor plus PD-1 inhibitor?
• What evidence did the prescribing team rely on?
• What is the next step if response lasts only a few months?
• Would taking a MEK inhibitor now affect whether any later trial fits?